An overview of Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA | BSE: 524715) stock overview, dividend history, and fundamental details is detailed below:
1. Stock Overview
-
Current Market Price (CMP): ~₹1,945 per share
-
Market Capitalization: ~₹4.66 Lakh Crore (Large Cap)
-
52-Week High / Low: ₹2,046.90 / ₹1,548.00
-
Index Representation: Nifty 50, BSE Sensex
-
Sector: Pharmaceuticals & Biotechnology
2. Core Fundamental Metrics
| Metric | Value / Details |
| Face Value | ₹1.00 per share |
| P/E Ratio | ~38.6x |
| P/B Ratio | ~5.6x |
| Dividend Yield | ~0.82% |
| Promoter Holding | ~54.48% |
| Market Position | Largest pharmaceutical company in India by market share |
Key Business Strengths
-
Global Specialty & Branded Generics: Market leader in India, US specialty pharmaceuticals, and emerging international markets.
-
Diversified Portfolio: Strong presence across chronic and sub-chronic therapeutic segments (Dermatology, Ophthalmology, Cardiology, and CNS).
-
Robust R&D Investment: Consistent reinvestment into specialty pipeline, clinical trials, and complex formulations.
-
Healthy Balance Sheet: Strong operational cash generation and low net-debt profile.
3. Dividend Payout History
Sun Pharma has paid dividends regularly on an interim and final basis:
| Financial Year | Dividend Type | Amount Per Share (₹) | Record / Ex-Date |
| FY 2025–26 | Final Dividend | ₹5.00 | July 2026 |
| FY 2025–26 | Interim Dividend | ₹11.00 | February 2026 |
| FY 2024–25 | Final Dividend | ₹5.50 | July 2025 |
| FY 2024–25 | Interim Dividend | ₹10.50 | February 2025 |
| FY 2023–24 | Final Dividend | ₹5.00 | July 2024 |
| FY 2023–24 | Interim Dividend | ₹8.50 | February 2024 |
4. Financial Performance Highlights
-
Revenue Growth: Driven by expanding specialty product sales in the US market and consistent outperformance in domestic formulations.
-
Profitability: Maintains healthy operating margins (EBITDA margins typically >25–27%).
SEBI Compliance Note: ipoind.com is an independent financial analytics and primary market research portal provided solely for educational and informational purposes. We are NOT a SEBI-registered Investment Advisor or Research Analyst. Financial market investments, equity securities, and Initial Public Offerings (IPOs) carry inherent market risks.
Grey Market Premium (GMP) Notice: Figures regarding Grey Market Premium (GMP), Kostak rates, and subject-to-sauda deals reflect unofficial, unregulated over-the-counter market sentiment. These figures do not guarantee exchange listing prices or actual trading outcomes. Always evaluate official Draft Red Herring Prospectus (DRHP / RHP) documents filed with BSE/NSE and consult a certified financial advisor prior to executing financial bidding decisions.